Versant Venture Management, LLC
CIK:0001560009
Venture Capital
$3B AUM
8 holdings
San Francisco, CA, US, “description”:
Latest filing:Jun 30, 2025
Versant Venture Management LLC is a venture capital firm primarily focused on investing in healthcare and life sciences companies. The firm manages multiple venture capital funds and invests at both the early and late stages. While a detailed, current public description is not available in the provided search results, Versant is widely recognized in the biotechnology and healthcare investment community.
Investment Strategy
n/a
Top Buys
J
JBIOJade Biosciences, Inc.+$15.2M
C
CRSPCRISPR Therapeutics AG+$7.3M
S
SKYESkye Bioscience, Inc.+$5.2M
C
CTNMContineum Therapeutics, Inc.-$4.3M
T
TPSTTempest Therapeutics, Inc.+$1.8M
Top Sells
J
JBIOJade Biosciences, Inc.+$15.2M
C
CRSPCRISPR Therapeutics AG+$7.3M
S
SKYESkye Bioscience, Inc.+$5.2M
C
CTNMContineum Therapeutics, Inc.-$4.3M
T
TPSTTempest Therapeutics, Inc.+$1.8M
Top Holdings
G
GLUEMonte Rosa Therapeutics, Inc.+31.0%$25.5M
C
CRSPCRISPR Therapeutics AG+29.5%$24.2M
J
JBIOJade Biosciences, Inc.+18.6%$15.2M
S
SKYESkye Bioscience, Inc.+10.2%$8.4M
R
RPTXRepare Therapeutics, Inc.+4.5%$3.7M
Equity Positions (7)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
G GLUE | Monte Rosa Therapeutics, Inc. | 31.04% | $25.5M | 5,652,922 | $6.94 | $4.51 | -$734.9K |
C CRSP | CRISPR Therapeutics AG | 29.52% | $24.2M | 498,558 | $44.16 | $48.64 | +$7.3M |
J JBIO | Jade Biosciences, Inc. | 18.56% | $15.2M | 1,525,820 | $9.99 | $9.99 | +$15.2M |
S SKYE | Skye Bioscience, Inc. | 10.22% | $8.4M | 2,007,704 | $14.18 | $4.18 | +$5.2M |
R RPTX | Repare Therapeutics, Inc. | 4.48% | $3.7M | 2,646,657 | $10.58 | $1.39 | +$1.1M |
Industry Allocation
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
+60.6%
PHARMACEUTICAL PREPARATIONS
+19.6%